[Chloramphenicol](#)
Essential medicine status
Section:
[6. Anti-infective medicines 6.2. Antibacterials 6.2.1. Access group antibiotics](#)
ATC codes: [J01BA01](#)
EMLc
Indication
Bacterial meningitis ICD11 code: [8E71.0Z](#)
INN
Chloramphenicol
Medicine type
Chemical agent
Antibiotic groups
[ACCESS](#)
List type
Core
Additional notes
Oily suspension for injection formulation is only for the presumptive treatment of epidemic meningitis in children older than 2 years and in adults.
Formulations
Parenteral > General injections > IV: 1 g in vial powder for injection (sodium succinate)
Parenteral > General injections > IM: 500 mg in 2 mL ampoule oily suspension for injection
EML status history
First added in 2017 ([TRS 1006](#))
Changed in 2023 ([TRS 1049](#))
Sex
All
Age
Also recommended for children
Therapeutic alternatives
The recommendation is for this specific medicine
Patent information
Patents have expired in most jurisdictions
Read more [about patents.](#)
Wikipedia
[Chloramphenicol](#)
DrugBank
[Chloramphenicol](#)
Expert Committee recommendation
☐

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of new strength formulations of cefotaxime (powder for injection: 500 mg; 1 g; 2 g (as sodium) in vial) to the EML and EMLc. - the addition of a new strength formulation of ceftriaxone (powder for injection: 500 mg (as sodium) in vial) to the EML and EMLc. - the addition of new formulations of amoxicillin (dispersible, scored tablet, 250 mg and 500 mg) to the EMLc. - the deletion of oral formulations of chloramphenicol (capsule 250 mg and oral liquid 150 mg/5 mL (as palmitate)) from the EML and EMLc.
EML recommendations: Bacterial meningitis
First choice
Second choice
First choice
[cefotaxime](#)
[ceftriaxone](#)
[cefotaxime](#)
[ceftriaxone](#)
Second choice
[ampicillin](#)
[benzylpenicillin](#)
[amoxicillin](#)
[chloramphenicol](#)
[amoxicillin](#)
[ampicillin](#)
[benzylpenicillin](#)
[chloramphenicol](#)